Clinical Neuropathology Practice News
4-2012: levels of evidence for brain tumor biomarkers

Anna Sophie Berghoff1, Harald Stefanits1, Harald Heinzl2 and Matthias Preusser3

1Institute of Neurology and Comprehensive Cancer Center CNS Unit,
2Center for Medical Statistics, Informatics, and Intelligent Systems, and
3Department of Medicine I and Comprehensive Cancer Center CNS Unit,
Medical University of Vienna, Vienna, Austria

Abstract. The National Comprehensive Cancer Network (NCCN) recently published a task force report on the evaluation of the clinical utility of tumor biomarkers in oncology. In this report, common terminology and the use of levels of evidence scores to aid the evaluation of biomarker tests in oncology were proposed. Furthermore, the task force applied a level of evidence system to selected biomarkers of several cancer types. According to this system, the highest level of evidence, IA, is granted to a biomarker only if it has been evaluated in at least one adequately powered and specifically designed prospective controlled trial. For gliomas, only 1p/19q testing in oligodendrogial tumors was classified as IA by the NCCN task force. For all of the following biomarkers the present evidence level for clinical utility was regarded as lower than that of 1p/19q status: MGMT gene promoter methylation testing (glioblastoma), IDH mutation testing (diffusely growing gliomas), BRAF fusion testing (pilocytic astrocytoma) and CIMP testing (diffusely growing gliomas). The task force acknowledged that the exact application of levels of evidence needs further refinement. To our mind, the implementation of a brain tumor expert panel seems vital to evaluate the evidence levels of neurooncological biomarkers according to generally accepted criteria on a regular basis. Systematic identification of current research needs and widely accepted up-to-date recommendations for efficient biomarker application in everyday practice could be gained.

Background

In clinical medicine, biomarkers are defined as objectively measurable factors that provide information about a disease state, thus providing the possibility for diagnosis, prediction of patient outcome, choice of therapy or follow-up. A myriad of potential biomarkers have been proposed for gliomas, but almost none have translated into actual clinical use so far [1]. For some biomarkers, there is controversy about their clinical value. For example, O6-methylguanine-methyltransferase (MGMT) gene promoter methylation status is considered as predictive factor by some, while others regard it rather as prognostic parameter [2, 3]. Some criticize that, either way, the lack of consensus on the test to use and the undetermined or poor analytical performance (repeatability and reproducibility) of the various methods for MGMT testing significantly limits the clinical utility of this marker [4, 5, 6, 7].

The National Comprehensive Cancer Network (NCCN) recently published a task force report on the evaluation of the clinical utility of tumor biomarkers in oncology [8]. In this report, common terminology and the use of levels of evidence scores to aid the evaluation of biomarker tests in oncology were proposed. The group applied a level of evidence system to selected biomarkers of several tumor types including gliomas. This approach is of interest, as objective evaluation of biomarkers according to predefined criteria through an expert panel may facilitate research on and informed clinical use of biomarkers in neurooncology.

Terminology

Biomarkers have different properties. This complexity necessitates the imple-
mentation of a commonly agreed upon terminology [8]. Table 1 contains selected terms with high relevance for neurooncology. From a neuropathology perspective it is important to note that for almost none of the potential glioma biomarker tests proposed in the literature stringent analysis of their analytical validity has been performed. There is a strong need for well controlled studies on the performance of the various biomarker assays including inter-laboratory round robin studies (ring trials), because the analytical validity of a test is a prerequisite for its clinical utility.

### Level of evidence system

Several level of evidence systems for assessing tumor biomarkers have been suggested in previous publications. The NCCN Task Force Group created their levels of evidence system from a combination of the revised Tumor Marker Utility Grading System (TMGUS) and the levels of evidence grade for using archived tissue [8]. The highest level of evidence IA is considered only for a biomarker evaluated in at least one adequately powered prospective controlled trial.

### Application to glioma biomarkers

According to the NCCN Task Force Report, only 1p/19q testing in oligodendrogial tumors meets the criteria for IA level of evidence among potential glioma biomarkers, because randomized controlled trials support clinical validity and clinical utility of the test, and a practical consensus guideline on performing 1p/19q FISH analysis provides analytic validation [8, 9, 10]. However, in our opinion prospective studies specifically designed to assess the clinical performance of 1p/19q status and systematic studies on the analytical performance of 1p/19q testing are formally missing, although prospective 1p/19q testing was amended during the conduct of the therapeutic trial EORTC 26951 in order to assess the relation of 1p/19q with progression-free and overall survival [9]. For all of the following glioma biomarkers the evidence level was regarded as lower than of 1p/19q status (IIB) by the task force based on currently available data: isocitrate dehydrogenase (IDH) mutation testing (diffusely growing gliomas) [11, 12], MGMT gene promoter methylation testing (glioblastoma) [13], v-RAF murine sarcoma viral oncogene homolog B1 (BRAF) fusion testing (pilocytic astrocytoma) [14] and CpG island methylator phenotype (CIMP) testing (diffusely growing gliomas) [15]. The group acknowledged that the exact application of levels of evidence needs further refinement. In our opinion, more strict assessment of the analytical validity of biomarker tests is of central importance in brain tumors. Furthermore, inclusion of additional commonly used and novel emerging markers such as Ki67 tumor cell proliferation index (gliomas) [16, 17, 18], INI1 protein loss

| Terminus                  | Characterization                                                                 | Example/comment                                                                 | References |
|---------------------------|----------------------------------------------------------------------------------|----------------------------------------------------------------------------------|------------|
| Diagnostic marker         | Aids the sub-classification of a particular disease state                        | INI1 for AT/RT                                                                   | [19, 20]   |
| Prognostic marker         | Association with some clinical outcome, such as overall survival or recurrence-free survival, independent of the treatment rendered | IDH mutations in glioma                                                          | [11, 12]   |
| Predictive marker         | Predicts the activity of a specific class or type of therapy and helps to make specific treatment decisions | BRAF V600E mutation in melanoma brain metastases                                  | [22, 23]   |
| Analytical performance    | Accuracy, reliability, repeatability, and reproducibility of an assay           | Analytical performance has not been sufficiently investigated for most biomarkers in neurooncology | [1]        |
| Clinical performance      | Association of test result with clinical outcome                                | MGMT promoter methylation has shown correlation with patient survival times in several studies | [2, 3, 13] |
| Clinical utility          | Ability to improve clinical decision-making and patient outcomes                | MGMT promoter methylation is not used in the clinical setting in many centers, because the assay has shown insufficient analytical performance | [4, 6]     |
(atypical teratoid/rhabdoid tumor) [19, 20] or BRAF V600E mutation status (melanoma brain metastases) [21, 22, 23] seems desirable.

Conclusions

The adoption of biomarkers into everyday practice is challenging. For most potential glioma biomarkers, differences in the study design concerning the evaluation of analytic and clinical validity as well as the clinical utility make it difficult to draw unequivocal conclusions. As a result, only a small proportion of biomarkers have been adopted into everyday practice, whereas on enormous amount of biomarkers is stuck in the research pipeline. The NCCN Task Force Report applies for the first time levels of evidence to evaluate biomarkers in glioma.

To our mind, the implementation of a brain tumor expert panel seems vital to evaluate the evidence levels of neurooncological biomarkers according to generally accepted criteria on a regular basis. Systematic identification of current research needs and widely accepted up-to-date recommendations for efficient biomarker application in everyday practice could be gained.

References

[1] Hainfellner JA, Heinzl H. Neuropathological biomarker candidates in brain tumors: key issues for translational efficiency. Clin Neuropathol. 2010; 29: 41-54. PubMed

[2] Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent MJ, Wick W, Hegi ME. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol. 2010; 6: 39-51. PubMed

[3] Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Salmon EP, Bekele BN, Aldape KD. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro-oncol. 2010; 12: 116-121. PubMed

[4] Preusser M, Elezi L, Hainfellner JA. Reliability and reproducibility of PCR-based testing of O6-methylguanine-DNA methyltransferase gene (MGMT) promoter methylation status in formalin-fixed and paraffin-embedded neurosurgical biopsy specimens. Clin Neuropathol. 2008; 27: 388-390. PubMed

[5] Quillien V, Lavenu A, Karayvan-Tapon L, Carpentier C, Labussière M, Leximple T, Chiotot O, Wagger M, Honnorat J, Saikali S, Fina F, Sanson M, Figarella-Branger D. Comparative assessment of 5 methods (methylationspecific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltransferase in a series of 100 glioblastoma patients. Cancer. 2012. Epub ahead of print. PubMed

[6] Preusser M. MGMT analysis at DNA, RNA and protein levels in glioblastoma tissue. Histol Histopathol. 2009; 24: 511-518. PubMed

[7] von Deimling A, Koehlounov A, Hartmann C. The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol. 2011; 21: 74-87. PubMed

[8] Febbo PG, M Ladanyi, KD Aldape et al. NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw. 2006; 4: 2715-2722. PubMed

[9] van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bornoen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haanxma-Reiche H, Kros JM, van Kooiwenhoven MC, Yech CJ, Allgeier A, Lacombe D, Gorlia T. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006; 24: 116-121. PubMed

[10] Woehrer A, Sander P, Haberer C, Kern S, Maier H, Preusser M, Hartmann C, Kros JM, Hainfellner JA; Research Committee of the European Confederation of Neuropathological Societies. FISH-based detection of 1p 19q codeletion in oligodendroglial tumors: procedures and protocols for neuropathological practice – a publication under the auspices of the Research Committee of the European Confederation of Neuropathological Societies (Euro-CNS). Clin Neuropathol. 2011; 30: 47-55. PubMed

[11] Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herron J, Kintzer KW, Véclesuves CE, Vogelstein B, Bigner DD. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009; 360: 765-773. PubMed

[12] Preusser M, Capper D, Hartmann C; Euro-CNS Research Committee. IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee. Clin Neuropathol. 2011; 30: 217-230. PubMed

[13] Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352: 997-1003. PubMed

[14] Jones DT, Gronvich J, Lichter P, Wit O, Pfister SM. MAPK pathway activation in pilocytic astrocytoma. Cell Mol Life Sci. 2011. Epub ahead of print. PubMed

[15] Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Fujara K, Berman BP, Pan F, Pelloski CE, Salmen EP, Bhat KP, Verhaak RG, Hoadley
KA, Hayes DN, Perou CM, Schmidt HK, Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H, et al; Cancer Genome Atlas Research Network. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010; 17: 510-522. PubMed

[16] Preusser M, Hoeftberger R, Woehler A, Gelpi E, Kouwenhoven M, Kros JM, Sanson M, Idbah A, Brandes AA, Heinzl H, Gorlia T, Hainfellner JA, van den Bent M. Prognostic value of Ki67 index in anaplastic oligodendroglial tumours – a translational study of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Histopathology. 2012. Epub ahead of print. PubMed

[17] Preusser M, Heinzl H, Gelpi E, Höftberger R, Fischer I, Pipp I, Milenkovic I, Wöhrer A, Popovici F, Wolfberger S, Hainfellner JA. Ki67 index in intracranial ependymoma: a promising histopathological candidate biomarker. Histopathology. 2008; 53: 39-47. PubMed

[18] Torp SH, Alsaker M. Ki-67 immunoreactivity, basic fibroblastic growth factor (bFGF) expression, and microvessel density as supplementary prognostic tools in low-grade astrocytomas. An immunohistochemical study with special reference to the reliability of different Ki-67 antibodies. Pathol Res Pract. 2002; 198: 261-265. PubMed

[19] Haberler C, Laggner U, Slave I, Czech T, Ambros IM, Ambros PF, Budka H, Hainfellner JA. Immunohistochemical analysis of INI1 protein in malignant pediatric CNS tumors: Lack of INI1 in atypical teratoid/rhabdoid tumors and in a fraction of primitive neuroectodermal tumors without rhabdoid phenotype. Am J Surg Pathol. 2006; 30: 1462-1468. PubMed

[20] Judkins AR, Mauger J, Ht A, Rorke LB, Biegel JA. Immunohistochemical analysis of ISNFS/INI1 in pediatric CNS neoplasms. Am J Surg Pathol. 2004; 28: 644-650. PubMed

[21] Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C, Hasselblatt M, Louis DN, Korshunov A, Pfister S, Hartmann C, Paulus W, Reifenberger G, von Deimling A. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra- cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011; 121: 397-405. PubMed

[22] Capper D, Berghoff AS, Magerle M, Ilhan A, Wöhrer A, Hackl M, Pichler J, Pasch S, Meyer J, Habel A, Petzelbauer P, Birner P, von Deimling A, Preusser M. Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol. 2012; 123: 223-233. PubMed

[23] Falchook G, Long G, Kurzrock R, et al. RAF inhibitor dabrafenib (GSK2118436) is active in melanoma brain metastases, multiple BRAF genotypes and diverse cancers. Lancet. 2012. In press.